RenovaCare, Inc.

Equities

RCAR

US75988J1060

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 02:48:44 2024-04-25 pm EDT			5-day change	1st Jan Change
0.0001 ^USD	0.00%		0.00%	+9,900.00%

2022	RenovaCare, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	CI
2022	RenovaCare, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	CI

RenovaCare, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021

March 30, 2022 at 04:25 pm EDT

RenovaCare, Inc. reported earnings results for the full year ended December 31, 2021. For the full year, the company reported net loss was USD 4.47 million compared to USD 9.55 million a year ago. Basic loss per share from continuing operations was USD 0.05 compared to USD 0.11 a year ago.

Latest news about RenovaCare, Inc.

RenovaCare, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-18	CI
RenovaCare, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-12	CI
RenovaCare, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-12	CI
RenovaCare Announces Termination of StemCell Systems R&D Agreement	22-05-03	CI
RenovaCare, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-30	CI
RenovaCare, Inc. Auditor Raises 'Going Concern' Doubt	22-03-29	CI
RenovaCare, Inc. Announces Management Changes	22-03-24	CI
RenovaCare, Inc. Announces CFO Changes	22-03-24	CI
RenovaCare, Inc. Announces CEO Changes	22-03-24	CI
RenovaCare, Inc. Enters into A Research and Collaboration Agreement with Histocell, S.L	22-02-03	CI
RenovaCare, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-12	CI
Renovacare, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-03	CI
RenovaCare, Inc Provides Update on Clinical Trial for the SkinGun™ and CellMist™ System for Wound Healing	21-07-22	CI
RenovaCare, Inc. Clinical Trial to Start At U.S. Burn Centers	21-06-07	CI
Renovacare, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-07	CI
FDA Grants RenovaCare, Inc. Full Investigational Device Exemption Approval for Safety and Feasibility Clinical Trial	21-05-06	CI
RenovaCare, Inc. Announces Change of Chief Financial Officer	21-04-13	CI
Renovacare, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-31	CI
RenovaCare, Inc. Announces Executive Changes	21-03-30	CI
RenovaCare, Inc. Announces Executive Changes	21-03-30	CI
Renovacare, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-13	CI
Renovacare, Inc. Announces Board Changes	20-10-05	CI
Renovacare, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-13	CI
RenovaCare, Inc. Receives FDA Conditional IDE Approval of CellMist™ System and SkinGun™ Device, Enabling Clinical Study for Safety and Feasibility	20-08-11	CI
RenovaCare, Inc. Appoints Lydia M. Evans, M.D. to its Board of Directors	20-08-04	CI

Chart RenovaCare, Inc.

Duration

Period

More charts

Company Profile

RenovaCare, Inc. is a clinical-stage biotechnology company. The Company is focused on developing autologous (self-donated) stem cell therapies for the regeneration of human organs. The Company through its wholly owned subsidiary, RenovaCare Sciences Corp. is focusing on the research, development and commercialization of autologous (using a patientâs own cells) cellular therapies that can be used for medical and aesthetic applications. The Companyâs CellMist System is a cell isolation procedure that enzymatically renders stem cells from the patientâs own skin or other tissues. The resulting stem cell suspension is administered topically from the Companyâs novel solution sprayer device (the SkinGun) as a cell therapy for wounds including burns to facilitate healing. Its SkinGun spray device is an advanced technology, using a gentle positive-pressure air stream to spray the CellMist Solution onto wounds.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
RENOVACARE, INC.	+9,900.00%	8.74K
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs